Suscribirse

Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver - 11/09/11

Doi : 10.1016/S0002-9610(99)80067-1 
João V. Vitola, MD a, Dominique Delbeke, MD, PhD , a, Martin P. Sandler, MD a, Michelle G. Campbell, MD a, Thomas A. Powers, MD a, J. Kelly Wright, MD b, William C. Chapman, MD b, C. Wright Pinson, MD, MBA b
a From the Department of Radiology and Radiological Sciences (JW, DD, MPS, MGC, TAP), Department of Surgery, Vanderbilt University Medical Center and Veterans' Affairs Hospital, Nashville, Tennessee, USA 
b From the Division of Hepatobiliary Surgery and Liver Transplantation (JKW, WCC, CWP), Department of Surgery, Vanderbilt University Medical Center and Veterans' Affairs Hospital, Nashville, Tennessee, USA 

*Requests for reprints should be addressed to Dominique Delbeke, MD, PhD, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 21st and Garland Avenue, Nashville, Tennessee 37232-2675.

Presented at the 36th Annual Meeting of the Society for Surgery of the Alimentary Tract, San Diego, California, May 14–17, 1995.

Abstract

Background

Accurate detection of recurrent colorectal carcinoma remains a clinical challenge. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG) is an imaging technique that allows direct evaluation of cellular metabolism. 18F-fluorodeoxyglucose PET was compared to computed tomography (CT) and CT portography for staging metastatic colorectal carcinoma.

Patients and methods

Twenty-four patients previously treated for colorectal carcinoma who had suspected recurrence to the liver underwent an 18FDG PET scan of the entire body. All patients had either a CT scan of the abdomen (n = 17), a CT portogram (n = 18), or both (n = 11). The final diagnosis was obtained by tissue pathology in 19 patients and clinical follow-up in 5 patients.

Results

A total of 60 suspicious lesions were identified. Of the 55 intrahepatic lesions, 39 were malignant and 16 were benign. Of the 5 extrahepatic lesions, 4 were malignant. The 18FDG PET imaging had a higher accuracy (93%) than CT and CT portography (both 76%) in detecting metastatic disease to the liver, and detected unsuspected extrahepatic recurrence in 4 patients. Although the sensitivity of 18FDG PET (90%) was slightly lower than that of CT portography (97%), the specificity was much higher (100% versus 9%), including postsurgical sites. 18FDG PET altered surgical plans in 6 (25%) of 24 patients.

Conclusions

18FDG PET is extremely useful in staging patients with suspected metastatic colorectal carcinoma to the liver.

El texto completo de este artículo está disponible en PDF.

© 1996  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 171 - N° 1

P. 21-26 - janvier 1996 Regresar al número
Artículo precedente Artículo precedente
  • Glucose-induced islet hyperemia is mediated by nitric oxide
  • Stefan Moldovan, Edward Livingston, Ren Shang Zhang, Robert Kleinman, Paul Girth, F. Charles Brunicardi
| Artículo siguiente Artículo siguiente
  • Cryoablation of unresectable malignant liver tumors
  • Michail Shafir, Robert Shapiro, Max Sung, Richard Warner, Arthur Sicular, Adam Klipfei

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.